MDT

99.5

-0.24%↓

147.28

+1.07%↑

VEEV

244.14

+1.84%↑

HQY

97.26

0%↓

PHR.US

17.07

-2.68%↓

MDT

99.5

-0.24%↓

147.28

+1.07%↑

VEEV

244.14

+1.84%↑

HQY

97.26

0%↓

PHR.US

17.07

-2.68%↓

MDT

99.5

-0.24%↓

147.28

+1.07%↑

VEEV

244.14

+1.84%↑

HQY

97.26

0%↓

PHR.US

17.07

-2.68%↓

MDT

99.5

-0.24%↓

147.28

+1.07%↑

VEEV

244.14

+1.84%↑

HQY

97.26

0%↓

PHR.US

17.07

-2.68%↓

MDT

99.5

-0.24%↓

147.28

+1.07%↑

VEEV

244.14

+1.84%↑

HQY

97.26

0%↓

PHR.US

17.07

-2.68%↓

Начало・Списък с акции・Adaptive Biotechnologies Corp

Adaptive Biotechnologies Corp

Отворен

16 -4.71

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

15.92

Максимум

16.87

Ключови измерители
By Trading Economics
Приходи	35M 9.5M
Продажби	35M 94M
Марж на печалбата	10.158
Служители	619
EBITDA	35M 17M

Препоръки
By TipRanks
Препоръки	Силна покупка
12-месечна прогноза	+21.04% upside

Дивиденти
By Dow Jones
Следващи печалби	10.02.2026 г.

Пазарни показатели
By TradingEconomics
Пазарна капитализация	-172M 2.5B
Предишно отваряне	20.71
Предишно затваряне	16

Техническа оценка

By Trading Central

Увереност

Very Strong Bullish Evidence

8.81 / 10.18 Подкрепа & съпротива

Adaptive Biotechnologies Corp Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

7.01.2026 г., 23:11 ч. UTC

Печалби

Samsung Electronics Expects Record Fourth-Quarter Profit Beat

7.01.2026 г., 22:55 ч. UTC

Значими двигатели на пазара

Defense Stocks Rebound After Trump Says He Wants $1.5 Trillion Military Budget in 2027

7.01.2026 г., 21:39 ч. UTC

Значими двигатели на пазара

Raytheon Down Following Trump Post Criticizing Company

7.01.2026 г., 20:13 ч. UTC

Значими двигатели на пазара

AbbVie, Revolution Medicines Stocks Gain on Report of Possible Acquisition

7.01.2026 г., 20:03 ч. UTC

Значими двигатели на пазара

Defense Contractor Shares Fall on Trump's Push to Ban Industry Dividends, Buybacks, Limit Executive Pay

7.01.2026 г., 23:46 ч. UTC

Пазарно говорене

Global Forex and Fixed Income Roundup: Market Talk

7.01.2026 г., 23:46 ч. UTC

Пазарно говорене

Nikkei May Decline as China-Japan Tensions Linger -- Market Talk

7.01.2026 г., 23:42 ч. UTC

Придобивния, сливания и поглъщания

Warner Discovery Rejects Paramount's Amended Hostile Bid -- 5th Update

7.01.2026 г., 23:34 ч. UTC

Пазарно говорене

Gold Edges Higher Amid Lingering Geopolitical Risks -- Market Talk

7.01.2026 г., 23:29 ч. UTC

Придобивния, сливания и поглъщания

Constellation Closes Deal for Calpine, Creating Biggest Electricity Generator -- Barrons.com

7.01.2026 г., 22:48 ч. UTC

Пазарно говорене

Infratil's Discount to Net Asset Value Too Good to Ignore -- Market Talk

7.01.2026 г., 22:46 ч. UTC

Печалби

Samsung Electronics Estimates 2025 Rev KRW332.770T Vs KRW300.870T >005930.SE

7.01.2026 г., 22:45 ч. UTC

Печалби

Samsung Electronics Estimates 2025 Oper Pft KRW43.530T Vs KRW32.730T >005930.SE

7.01.2026 г., 22:43 ч. UTC

Придобивния, сливания и поглъщания

Revolution Medicines Draws Takeover Interest -- 2nd Update

7.01.2026 г., 22:42 ч. UTC

Печалби

Samsung Electronics 4Q Oper Pft Estimate Beat FactSet-Compiled Consensus Forecast

7.01.2026 г., 22:41 ч. UTC

Печалби

Samsung Electronics Sees 4Q Oper Pft KRW20.000T Vs KRW6.490T >005930.SE

7.01.2026 г., 22:41 ч. UTC

Печалби

Samsung Electronics Sees 4Q Rev KRW93.000T Vs KRW75.790T >005930.SE

7.01.2026 г., 22:40 ч. UTC

Значими двигатели на пазара

Defense Stocks Rebound After Trump Says He Wants $1.5T Military Budget in 2027

7.01.2026 г., 22:31 ч. UTC

Пазарно говорене

Macro Tailwinds Strengthen for Chalice Mining -- Market Talk

7.01.2026 г., 22:22 ч. UTC

Пазарно говорене

Northern Star's Run of Disruptions Increasingly a Concern -- Market Talk

7.01.2026 г., 22:01 ч. UTC

Пазарно говорене

Valuations of New Zealand Property Stocks Supportive -- Market Talk

7.01.2026 г., 21:50 ч. UTC

Пазарно говорене

Basic Materials Roundup: Market Talk

7.01.2026 г., 21:46 ч. UTC

Пазарно говорене

Northern Star's Revised Guidance Looks Achievable -- Market Talk

7.01.2026 г., 21:22 ч. UTC

Придобивния, сливания и поглъщания

Eli Lilly to Buy Ventyx Biosciences for $14 a Share >LLY VTYX

7.01.2026 г., 21:18 ч. UTC

Придобивния, сливания и поглъщания

Lilly To Acquire Ventyx Biosciences To Advance Oral Therapies Targeting Inflammatory-mediated Diseases >LLY VTYX

7.01.2026 г., 21:05 ч. UTC

Придобивния, сливания и поглъщания

Warner Discovery Rejects Paramount's Amended Hostile Bid -- 4th Update

7.01.2026 г., 20:29 ч. UTC

Придобивния, сливания и поглъщания

AbbVie Near Deal for Revolution Medicines -- Update

7.01.2026 г., 20:27 ч. UTC

Пазарно говорене

U.S. Natural Gas Futures Snap Losing Streak -- Market Talk

7.01.2026 г., 19:58 ч. UTC

Пазарно говорене

Oil Falls As U.S. to Receive Sanctioned Venezuelan Crude -- Market Talk

7.01.2026 г., 19:48 ч. UTC

Значими двигатели на пазара

Defense Contractor Shares Fall on Trump's Push to Ban Industry Dividends, Buybacks, Limit Exec Pay

Сравнение с други в отрасъла

Ценова промяна

Adaptive Biotechnologies Corp Прогноза

Ценова цел

By TipRanks

21.04% нагоре

12-месечна прогноза

Среден 20.25 USD 21.04%

Висок 21 USD

Нисък 20 USD

Според 6 анализатори от Wall Street, предложили 12-месечна ценова цел за Adaptive Biotechnologies Corp през последните три месеца.

Консенсусна оценка

By TipRanks

Силна покупка

6 ratings

Купи

Задържане

Продай

Според 6 анализатори, дали борсови рейтинги на Adaptive Biotechnologies Corp през последните 3 месеца.

Техническа оценка

By Trading Central

8.81 / 10.18Подкрепа & съпротива

Recent bullish events outweigh bearish events.

All events are bullish.

There is one bullish event.

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно Adaptive Biotechnologies Corp

Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunosequencing platform which combines a suite of proprietary chemistry, computational biology, and machine learning to generate clinical immunomics data to decode the adaptive immune system. It also provides clonoSEQ diagnostic test which detects and monitors the remaining number of cancer cells that are present in a patient's body during and after treatment, known as Minimal Residual Disease (MRD). The company offers products and services for life sciences research, clinical diagnostics, and drug discovery applications. Adaptive Biotechnologies Corporation has strategic collaborations with Genentech, Inc. for the development, manufacture, and commercialization of neoantigen directed T cell therapies for the treatment of a range of cancers; and Microsoft Corporation to develop diagnostic tests for the early detection of various diseases from a single blood test. The company was formerly known as Adaptive TCR Corporation and changed its name to Adaptive Biotechnologies Corporation in December 2011. Adaptive Biotechnologies Corporation was incorporated in 2009 and is headquartered in Seattle, Washington.